EGFR Exon 20 Insertion as a Therapeutic Target in Non-small Cell Lung Cancer

Joel Neal, MD, PhD, and Alexander I Spira, MD, PhD, FACP, discuss the recent identification of EGFR exon 20 insertion+ mNSCLC and how patients responded before the new drugs were introduced.

A discussion on how this variant of NSCLC differs from the (exon 19 and exon 21) EGFR mutations and the demographics of EGFR patients.

Experts review the demographics of patients who should be tested and how to discuss EGFR Exon 20 Insertion+ NSCLC with patients.

Joel Neal, MD, PhD, and Alexander I Spira, MD, PhD, FACP, review current treatments for EGFR Exon 20 Insertion+ NSCLC, their preferred treatments, and current clinical trials.

An explanation of the EXCLAIM Trial and the mechanism of action, clinical development, and the overall clinical development program of mobocertinib.

Joel Neal, MD, PhD, and Alexander I Spira, MD, PhD, FACP, review amivantamab and poziotinib as other treatment options for EGFR Exon 20 Insertion+ NSCLC.

Experts review the toxicity of mobocertinib and further discuss the key findings from the EXCLAIM Trial.

Joel Neal, MD, PhD, and Alexander I Spira, MD, PhD, FACP, provide an overview of their major conclusions and clinical pearls for the treatment approach of EGFR Exon 20 Insertion+ NSCLC.